aJohnson and Johnson Pharmaceutical Research and Development, Raritan, New Jersey
bMillennium Pharmaceuticals, Inc., Cambridge, Massachusetts
cDana-Farber Cancer Institute, Boston, Massachusetts, USA
dJohnson and Johnson Pharmaceutical Research and Development, Beerse, Belgium
eCentre René Gauducheau, Nantes/St Herblain, France
Correspondence to Deborah S. Ricci, PhD, Johnson and Johnson Pharmaceutical Research and Development, 920 Route 202, Raritan, NJ 08869, USA Tel: +1 908 218 7482; fax: +1 908 526 1242; e-mail: [email protected]
Reyna Favis and Yu Sun contributed equally to the study.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (www.pharmacogeneticsandgenomics.com).
Received August 17, 2010
Accepted December 5, 2010